**Proteins** 

# **Product** Data Sheet



# **TP-021**

Cat. No.: HY-119402 CAS No.: 2130878-25-8 Molecular Formula:  $C_{20}H_{20}CIN_3O_5$ Molecular Weight: 417.84

Target: **Bcl-2 Family** Pathway: Apoptosis

Storage: Powder -20°C

3 years 4°C 2 years

In solvent -80°C 6 months

> -20°C 1 month

### **SOLVENT & SOLUBILITY**

In Vitro DMSO : ≥ 50 mg/mL (119.66 mM)

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.3933 mL	11.9663 mL	23.9326 mL
	5 mM	0.4787 mL	2.3933 mL	4.7865 mL
	10 mM	0.2393 mL	1.1966 mL	2.3933 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.71 mg/mL (1.70 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description	TP-021 (BCL6-IN-8c) is a potent and orally active B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor with an IC $_{50}$ of 0.10 $\mu$ M in cell-free enzyme-linked immunosorbent assay <sup>[1]</sup> .	
IC <sub>50</sub> & Target	IC50: 0.10 $\mu$ M (BCL6-corepressor interaction) $^{[1]}$	
In Vitro	TP-021 (BCL6-IN-8c, Compound 8c) also exhibits good cellular PPI inhibitory activity in the submicromolar range (M2H IC $_{50}$ = 0.72 $\mu$ M). TP-021 (BCL6-IN-8c) does not exhibit significant cytotoxicity even at 30 $\mu$ M $^{[1]}$ . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	The pharmacokinetic profile of TP-021 (BCL6-IN-8c, Compound 8c) is evaluated by a mouse cassette-dosing study (0.1 mg/kg iv; 1 mg/kg po). TP-021 (BCL6-IN-8c) exhibits a good pharmacokinetic profile ( $C_{max} = 233 \text{ ng/mL}$ , $T_{max} = 2 \text{ hours}$ , MRT	

= 3.3 h, AUC = 1.27 mg $\cdot$ h/mL, F (oral bioavailability) = 79.9%)<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

[1]. Yasui T, et al. Discovery of a novel B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor by utilizing structure-based drug design. Bioorg Med Chem. 2017 Sep 1;25(17):4876-4886.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com